Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease and has emerged as a public health emergency of international concern. As of this time, there are no specific antiviral therapies available for the treatment of COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits. Statins have been widely reported to exert antiviral activity against many enveloped viruses by inhibiting the cholesterol biosynthesis pathway. Cholesterol likewise contributes to the coronavirus’s life cycle, including viral entry, fusion and budding. In addition, statins have been ascribed beneficial anti-inflammatory, immunomodulatory effects and promote haemodynamic stability. Therefore, statins, which are cholesterol-lowering drugs with anti-inflammatory, immunomodulatory and antiviral properties, may play a role in SARS-CoV-2 therapy. The aim of the present minireview was to delineate the potential beneficial therapeutic effects of statins in treating SARS-CoV-2 infections. Nevertheless, large, randomised trials are needed to confirm the beneficial effects and safety profile of the statins in patients with SARS-CoV-2.
AndrusMREastJ. (2010) Use of statins in patients with chronic Hepatitis C. Southern Medical Journal103: 1018–1024.
2.
BarmanSNayakDP. (2007) Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. Journal of Virology81(22): 12169–12178.
3.
Blanco-ColioLMTuñónJMartín-VenturaJLEgidoJ. (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney International63(1): 12–23.
4.
CalistoKLCarvalho BdeMRopelleERMittestainerFCCamachoACGuadagniniDCarvalheiraJBSaadMJ. (2010) Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling. PLoS One5: e14232.
5.
CaoX. (2020) COVID-19: immunopathology and its implications for therapy. Nature Reviews. Immunology20: 269–270.
6.
del RealGJiménez-BarandaSMiraELacalleRALucasPGómez-MoutónCAlegretMPeñaJMRodríguez-ZapataMÁlvarez-MonMMartínez-ACMañesS. (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. Journal of Experimental Medicine200: 541–547.
7.
EspañoENamJHSongEJSongDLeeCKKimJK. (2019) Lipophilic statins inhibit Zika virus production in Vero cells. Scientific Reports9(1): 11461.
8.
GlendeJSchwegmann-WesselsCAl-FalahMPfefferleSQuXDengHDrostenCNaimHYHerrlerG. (2008) Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology381: 215–221.
9.
GrahamDRChertovaEHilburnJMArthurLOHildrethJE. (2003) Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. Journal of Virology77(15): 8237–8248.
10.
GuiQYangYZhangJ. (2017) Effects of statins on the development of sepsis and organ dysfunction in hospitalized older patients in China. Brazilian Journal of Infectious Diseases21(3): 255–262.
11.
HuangCWangYLiXRenLZhaoJHuYZhangLFanCXuJGuXChengZYuTXiaJWeiYWuWXieXYinWLiHLiuMXiaoYGaoHGuoLXieJWangGJiangRGaoZJinQWangJCaoB. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 15;395(10223): 497–506.
12.
HuangHLiYSadaokaTTangHYamamotoTYamanishiKMoriY. (2006) Human herpesvirus 6 envelope cholesterol is required for virus entry. Journal of General Virology87(Pt 2): 277–285.
13.
LevineL. (2003) Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids in Health and Disease2: 1.
14.
LiuBLiMZhouZGuanXXiangY. (2020) Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?Journal of Autoimmunity10: 102452.
15.
LiuS-YAliyariRChikereKLiGMarsdenMDSmithJKPernetOGuoHNusbaumRZackJAFreibergANSuLLeeBChengG. (2013) Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity38: 92–105.
16.
LuYLiuDXTamJP. (2008) Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochemical and Biophysical Research Communications369(2): 344–349.
17.
Martínez-GutierrezMCastellanosJEGallego-GómezJC. (2011) Statins reduce dengue virus production via decreased virion assembly. Intervirology54: 202–216.
18.
MehrbodPOmarARHair-BejoMHaghaniAIderisA. (2014) Mechanisms of action and efficacy of statins against influenza. Biomed Research International2014: 872370.
19.
MilletJKWhittakerGR. (2018) Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology. 517:3-8.
20.
MoghadasianMH. (1999) Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sciences65: 1329–1337.
21.
NovackVEisingerMFrenkelATerblancheMAdhikarNDouvdevaniAAmicharyDAlmogY. (2009) The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Medicine35: 1255–1260.
22.
OnoA. (2010) Relationships between plasma membrane microdomains and HIV-1 assembly. Biology of the Cell102(6): 335–350.
23.
OvertonETSterrettSWestfallAOKahanSMBurkholderGZajacAJGoepfertPABansalA. (2014) Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS28: 2627–2631.
24.
Shrivastava-RanjanPFlintMBergeronÉMcElroyAKChatterjeePAlbariñoCGNicholSTSpiropoulouCF. (2018) Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing. mBio9(3): e00660.
25.
SunXWhittakerGR. (2003) Role for influenza virus envelope cholesterol in virus entry and infection. Journal of Virology77(23): 12543–12551.
26.
SviridovDBukrinskyM. (2014) Interaction of pathogens with host cholesterol metabolism. Current Opinion in Lipidology25(5): 333–338.
27.
ThorpEBGallagherTM. (2004) Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. Journal of Virology78(6): 2682–2692.
28.
UlivieriCFanigliuloDBenatiDPasiniFLBaldariCT. (2008) Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation. European Journal of Immunology38(10): 2832–2844.
29.
VerpaalenBNeytsJDelangL. (2014) Are statins a viable option for the treatment of infections with the hepatitis C virus?Antiviral Research105: 92–99.
30.
WolfMCFreibergANZhangTAkyol-AtamanZGrockAHongPWLiJWatsonNFFangAQAguilarHCPorottoMHonkoANDamoiseauxRMillerJPWoodsonSEChantasirivisalSFontanesVNegreteOAKrogstadPDasguptaAMosconaAHensleyLEWhelanSPFaullKFHolbrookMRJungMELeeB. (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences of the United States of America107: 3157–3162.
31.
XuZShiLWangYZhangJHuangLZhangCLiuSZhaoPLiuHZhuLTaiYBaiCGaoTSongJXiaPDongJZhaoJWangFS. (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Medicine8: 420–422.
32.
YanBChuHYangDSzeKHLaiPMYuanSShuaiHWangYKaoRYChanJFYuenKY. (2019) Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses11(1): 73.
33.
YaoXHLiTYHeZCPingYFLiuHWYuSCMouHMWangLHZhangHRFuWJLuoTLiuFGuoQNChenCXiaoHLGuoHTLinSXiangDFShiYPanGQLiQRHuangXCuiYLiuXZTangWPanPFHuangXQDingYQBianXW. (2020) A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi49: E009.
34.
YuanS. (2015) Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio6(4): e01120.
